AstraZeneca Pharma India and Mankind Pharma entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.
Mankind has a distribution network including close to 16,000 field force and more than 13,000 stockists across India.
AstraZeneca is present in therapy areas including Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease in India .
Mankind has a distribution network including close to 16,000 field force and more than 13,000 stockists across India.
AstraZeneca is present in therapy areas including Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease in India .
The post appeared first on .